NO945015L - Substituerte 1-okso-1,2-dihydro-isochinolinoyl- og 1,1-diokso-2H-1,2-benzotiazinoylguanidiner, fremgangsmåte for fremstilling og anvendelse som medikament eller diagnostikum - Google Patents

Substituerte 1-okso-1,2-dihydro-isochinolinoyl- og 1,1-diokso-2H-1,2-benzotiazinoylguanidiner, fremgangsmåte for fremstilling og anvendelse som medikament eller diagnostikum

Info

Publication number
NO945015L
NO945015L NO945015A NO945015A NO945015L NO 945015 L NO945015 L NO 945015L NO 945015 A NO945015 A NO 945015A NO 945015 A NO945015 A NO 945015A NO 945015 L NO945015 L NO 945015L
Authority
NO
Norway
Prior art keywords
dihydroisoquinolinoyl
benzothiazinoylguanidines
dioxo
oxo
medicament
Prior art date
Application number
NO945015A
Other languages
English (en)
Other versions
NO945015D0 (no
NO304787B1 (no
Inventor
Andreas Weichert
Heinz-Werner Kleemann
Hans-Jochen Lang
Jan-Robert Schwark
Udo Albus
Wolfgang Scholz
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO945015D0 publication Critical patent/NO945015D0/no
Publication of NO945015L publication Critical patent/NO945015L/no
Publication of NO304787B1 publication Critical patent/NO304787B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/64Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/021,2-Thiazines; Hydrogenated 1,2-thiazines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Compression, Expansion, Code Conversion, And Decoders (AREA)
NO944747A 1993-12-24 1994-12-23 Substituerte 1-okso-1,2-dihydro-isochinolinoyl- og 1,1-diokso-2H-1,2-benzotiazinoylguanidiner og anvendelse av forbindelsene for fremstilling av medikamenter NO304787B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4344550A DE4344550A1 (de) 1993-12-24 1993-12-24 Substituierte 1-Oxo-1,2-dihydro-isochinolinoyl- und 1,1-Dioxo-2H-1,2-benzothiazinoylguanidine, Verfahrenzu ihrer Herstellung, ihre Verwendung als Medikamentt oder Diagnostikum sowie sie enthaltendes Medikamen

Publications (3)

Publication Number Publication Date
NO945015D0 NO945015D0 (no) 1994-12-23
NO945015L true NO945015L (no) 1995-06-26
NO304787B1 NO304787B1 (no) 1999-02-15

Family

ID=6506276

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944747A NO304787B1 (no) 1993-12-24 1994-12-23 Substituerte 1-okso-1,2-dihydro-isochinolinoyl- og 1,1-diokso-2H-1,2-benzotiazinoylguanidiner og anvendelse av forbindelsene for fremstilling av medikamenter

Country Status (20)

Country Link
US (1) US5547953A (no)
EP (1) EP0659748B1 (no)
JP (1) JP3790559B2 (no)
KR (2) KR100360127B1 (no)
CN (1) CN1053899C (no)
AT (1) ATE194605T1 (no)
AU (1) AU683320B2 (no)
CA (1) CA2138466A1 (no)
DE (2) DE4344550A1 (no)
DK (1) DK0659748T3 (no)
ES (1) ES2149233T3 (no)
FI (1) FI946039L (no)
GR (1) GR3034335T3 (no)
HU (1) HU222524B1 (no)
IL (1) IL112114A (no)
NO (1) NO304787B1 (no)
NZ (2) NZ270264A (no)
PT (1) PT659748E (no)
TW (1) TW504505B (no)
ZA (1) ZA9410242B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4412334A1 (de) * 1994-04-11 1995-10-19 Hoechst Ag Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP0765867A1 (de) * 1995-09-27 1997-04-02 Hoechst Aktiengesellschaft Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Antiarrhytmika oder Diagnostikum sowie sie enthaltendes Medikament
DE19540995A1 (de) * 1995-11-03 1997-05-07 Hoechst Ag Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19542306A1 (de) * 1995-11-14 1997-05-15 Hoechst Ag Sulfonylamino-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
PL316439A1 (en) * 1995-11-20 1997-05-26 Hoechst Ag Novel substituted derivatives of benzoyloguanidine, method of obtaining them, their application in production of pharmaceutic and diagnostic agents and pharmaceutic agent as such
DE19546736A1 (de) * 1995-12-14 1997-06-19 Hoechst Ag Substituierte Chromanylsulfonyl(thio)harnstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Präparate
DE19548708A1 (de) * 1995-12-23 1997-06-26 Merck Patent Gmbh Cyclische Sulfone
CA2195697A1 (en) 1996-02-02 1997-08-03 Masahumi Kitano Novel substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof
JPH10152481A (ja) * 1996-09-25 1998-06-09 Kanebo Ltd ベンゾ[1,4]チアジン誘導体およびそれからなる医薬
US6436927B1 (en) 1997-02-12 2002-08-20 Smithkline Beecham Corporation IL-8 receptor antagonists
DE69824837T2 (de) * 1997-02-12 2005-08-25 Smithkline Beecham Corp. Il-8-rezeptor-antagonisten
JP3652708B2 (ja) 1997-03-06 2005-05-25 トーアエイヨー株式会社 シクロアルカ[b]ピリジン−3−カルボニルグアニジン誘導体、その製造法およびそれを含有する医薬品
JP2002502414A (ja) * 1997-06-02 2002-01-22 藤沢薬品工業株式会社 細胞中のNa▲上+▼/H▲上+▼交換の阻害剤としてのグアニジン誘導体
US6703405B2 (en) 2001-12-22 2004-03-09 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as a medicament, and medicament containing them
DE10163914A1 (de) * 2001-12-22 2003-07-03 Aventis Pharma Gmbh Substituierte 4-Phenyltetrahydroisochinolinium-Salze, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
WO2006044645A2 (en) * 2004-10-13 2006-04-27 Adolor Corporation Sulfamoyl benzamides and methods of their use
SI2648511T1 (sl) 2010-12-08 2017-11-30 Lycera Corporation Pirazolil gvanidinski inhibitorji F1F0-ATPaze in njihove terapevtske uporabe
US9169199B2 (en) 2010-12-08 2015-10-27 Lycera Corporation Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
ES2591156T3 (es) 2010-12-08 2016-11-25 Lycera Corporation Inhibidores de F1F0-ATPasas de tipo piridonil guanidina y sus usos terapéuticos
WO2013185048A2 (en) 2012-06-08 2013-12-12 Lycera Corporation Heterocyclic guanidine f1f0-atpase inhibitors and therapeutic uses thereof
US9920012B2 (en) 2012-06-08 2018-03-20 Lycera Corporation Indazole guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
US9580391B2 (en) 2012-06-08 2017-02-28 Lycera Corporation Saturated acyl guanidine for inhibition of F1F0-ATPase
AU2014363958B2 (en) 2013-12-10 2018-11-08 Lycera Corporation Alkylpyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
MX2016007445A (es) 2013-12-10 2016-09-09 Lycera Corp Inhibidores de f1f0-atpasa de trifluorometil pirazolil guanidina y usos terapeuticos de los mismos.
CA2931792A1 (en) 2013-12-10 2015-06-18 Lycera Corporation N-substituted pyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3780027A (en) * 1970-04-29 1973-12-18 Merck & Co Inc Anthranilic acid derivatives
DE3929582A1 (de) * 1989-09-06 1991-03-07 Hoechst Ag Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament
EP0556674B1 (de) * 1992-02-15 1996-06-19 Hoechst Aktiengesellschaft 3,5-Substituierte Benzoylguanidine, mit antiarrythmischer Wirkung und inhibierender Wirkung auf die Proliferationen von Zellen
DK0589336T3 (da) * 1992-09-22 1997-06-16 Hoechst Ag Benzylguanidiner, fremgangsmåde til deres fremstilling samt deres anvendelse som antiarytmetika
DE69329787T2 (de) * 1992-09-28 2001-06-13 Hoechst Ag Antiarrhythmische und cardioprotektive substituierte 1(2H)-Isochinoline, Verfahren zu deren Herstellung, diese enthaltende Arzneimittel und ihre Anwendung für die Herstellung eines Arzneimittels zur Behandlung von Herzinsuffizienzen
TW250479B (no) * 1992-12-15 1995-07-01 Hoechst Ag

Also Published As

Publication number Publication date
NZ272846A (en) 1996-02-27
IL112114A (en) 2001-06-14
ATE194605T1 (de) 2000-07-15
AU8170094A (en) 1995-06-29
PT659748E (pt) 2000-11-30
FI946039A7 (fi) 1995-06-25
FI946039A0 (fi) 1994-12-22
NO945015D0 (no) 1994-12-23
FI946039L (fi) 1995-06-25
ES2149233T3 (es) 2000-11-01
DE59409439D1 (de) 2000-08-17
KR100353339B1 (ko) 2002-09-19
HUT72749A (en) 1996-05-28
KR100360127B1 (ko) 2003-04-23
ZA9410242B (en) 1995-08-02
US5547953A (en) 1996-08-20
CA2138466A1 (en) 1995-06-25
AU683320B2 (en) 1997-11-06
IL112114A0 (en) 1995-03-15
HU9403759D0 (en) 1995-02-28
EP0659748A1 (de) 1995-06-28
KR950017981A (ko) 1995-07-22
NO304787B1 (no) 1999-02-15
JPH07206823A (ja) 1995-08-08
CN1107840A (zh) 1995-09-06
EP0659748B1 (de) 2000-07-12
DK0659748T3 (da) 2000-10-02
JP3790559B2 (ja) 2006-06-28
GR3034335T3 (en) 2000-12-29
TW504505B (en) 2002-10-01
HU222524B1 (hu) 2003-08-28
CN1053899C (zh) 2000-06-28
NZ270264A (en) 1996-02-27
DE4344550A1 (de) 1995-06-29

Similar Documents

Publication Publication Date Title
NO945015D0 (no) Substituerte 1-oxo-1,2-dihydro-isochinolinoyl- og 1,1-dioxo-2H-1,2-benzotiazinoylguanidiner, fremgangsmåte for fremstilling og anvendelse som medikament eller diagnostikum
DK0612723T3 (da) Substituerede benzoylguanidiner, fremgangsmåde til fremstilling, deres anvendelse som lægemiddel, som inhibitor af den cellulære Na+/H+-udbytning eller som diagnostikum samt lægemiddel med indhold deraf
DK159322C (da) Analogifremgangsmaade til fremstilling af 4ae-epi-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin a eller farmaceutisk acceptable syreadditionssalte deraf og 4ae-epi-9-deoxy-9a-aza-9a-homoerythromycin a til anvendelse som udgangsmateriale ved fremgangsmaaden
ATE205390T1 (de) Verbesserung der glukosetoleranz
KR890014507A (ko) 티아졸리딘디온 혈당강하제
NO934634L (no) 3,5-substiturete aminobenzoylguanidiner, fremgangsmåte til fremstilling derav, deres anvendelse som medikament eller diagnostikum samt middel inneholdende forbindelsene
NZ238181A (en) N-(1-substituted-piperidinyl(alkyl))carbamic acid, urea and carboxamide derivatives and homologues thereof; preparatory processes and pharmaceutical compositions
FI920271A0 (fi) Polyamintioler som straolningsskyddande aemnen.
BR9503536A (pt) Composto processo para sua preparação seu uso e composição farmacêutica
KR920703512A (ko) 단백질 활성효소 c(protein kinase c)를 방해하는 1, 4-비스-(아미노-하이드록시알킬아미노)-안트라퀴논
CO4290351A1 (es) Proceso
ATE192141T1 (de) Aromatische hydroxamsäure-verbindungen, ihre herstellung und verwendung
DE59107500D1 (de) Neue Beta-Galactosidase-Substrate für den CEDIA
BR8208033A (pt) Processo quimico
CA2111096A1 (en) Thiazolidinedione Hypoglycemic Agents
NO983609L (no) N-(3,3-dimetylbutyl)-L-aspartyl-D-<alfa>-aminoalkansyre-N-(S)-1-fenyl-alkanamid anvendelig som s°tningsmiddel
KR910000645A (ko) 개선된 경련치료제
ES538230A0 (es) Procedimiento para la preparacion de nuevos derivados de n-(metoxifenacil)-amina
NO943861D0 (no) Trisyklisk forbindelse til bruk som tachykinin-antagonist
DK289587A (da) Agrokemisk mikrobicid
SE8006142L (sv) 1,2,4-triazol-3-tioler
DE3462030D1 (en) Derivatives of beta-û2-(halogenobenzyl)-phenoxy¨- ethylamine,process for their preparation and their therapeutical use.
FI955282A0 (fi) Menetelmä NG-monoalkyyli-L-arginiinin ja vastaavien yhdisteiden valmistamiseksi
NO942350L (no) Peptidforbindelse med terapeutisk aktivitet